Provided by Tiger Trade Technology Pte. Ltd.

ResMed

218.27
-1.3100-0.60%
Post-market: 218.270.00000.00%19:30 EDT
Volume:912.33K
Turnover:198.92M
Market Cap:31.49B
PE:20.93
High:221.29
Open:220.44
Low:215.97
Close:219.58
52wk High:284.87
52wk Low:180.27
Shares:144.25M
Float Shares:143.49M
Volume Ratio:0.71
T/O Rate:0.64%
Dividend:2.40
Dividend Rate:1.10%
EPS(TTM):10.43
EPS(LYR):10.43
ROE:24.27%
ROA:14.00%
PB:4.78
PE(LYR):20.93

Loading ...

'I'm the Executor': My Two Siblings and I Inherited an IRA. Can We Just Cash it Out?

Dow Jones
·
Sep 12

'I'm the Executor': My Two Siblings and I Inherited an IRA. Can We Just Cash it Out?

Dow Jones
·
Sep 11

ResMed CEO Michael Farrell Exercises Options and Sells Shares Under 10b5-1 Plan

TIPRANKS
·
Sep 11

Resmed Inc.-Statement of Changes in Beneficial Ownership

THOMSON REUTERS
·
Sep 11

Statement of Changes in Beneficial Ownership-RMD.N

Reuters
·
Sep 11

ResMed CEO Michael J. Farrell Disposes of Common Shares Worth $1,110,188.53

Reuters
·
Sep 10

ResMed price target raised to $240 from $235 at Citi

TIPRANKS
·
Sep 10

Citigroup Adjusts Price Target on ResMed to $240 From $235, Keeps Neutral Rating

MT Newswires Live
·
Sep 10

'I'm the Executor': My Two Siblings and I Inherited an IRA. Can We Just Cash it Out?

Dow Jones
·
Sep 10

ResMed Inc. Stock Falls Tuesday, Underperforms Market

Dow Jones
·
Sep 09

Resmed Inc Stock (RMD) Moved Down by 3.15% on Sep 8: What Investors Need To Know

TradingKey
·
Sep 09

'I'm the Executor': My Two Siblings and I Inherited an IRA. Can We Just Cash it Out?

Dow Jones
·
Sep 08

'I'm the Executor': My Two Siblings and I Inherited an IRA. Can We Just Cash it Out?

Dow Jones
·
Sep 07

ResMed Adjusts CDI and Share Counts Amid Cross-Market Transfers and Buybacks

TIPRANKS
·
Sep 07

Statement of CDIs on Issue - RMD-RMD.N

Reuters
·
Sep 07

Resmed Inc.-Statement of Changes in Beneficial Ownership

THOMSON REUTERS
·
Sep 07

Statement of Changes in Beneficial Ownership-RMD.N

Reuters
·
Sep 07

ResMed Director Peter C. Farrell Disposes of 970 Common Shares Worth $227,688.10

Reuters
·
Sep 04

Morgan Stanley Adjusts Price Target on ResMed to $225 From $227, Keeps Equalweight Rating

MT Newswires Live
·
Sep 03

Is ResMed (RMD) Below Fair Value On The MatrixCare Sale?

Simply Wall St.
·
Sep 02